Aurinia Pharmaceuticals Inc.
AUPH- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001600620
In the last 90 days, Aurinia Pharmaceuticals Inc. insiders filed 0 open-market purchases and 2 sales; 282 institutions reported holding it in 13F filings for Q2 2026, worth $1.34B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Aurinia Pharmaceuticals Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 2 filings
- 1 insider, $546.4K in total
- Insiders trading
- 1
- Net value
- −$546.4K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Aurinia Pharmaceuticals Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Robertson Stephen P. | Chief Legal Officer | 588,848 | Sep 11, 2026 | 6 |
| Nova Tina Susan | Director | – | Jun 8, 2026 | 1 |
| Johnson Craig A | Director | 14,592 | Jun 8, 2026 | 2 |
| Bailey Jeffrey Allen | Director | 22,775 | Jun 8, 2026 | 2 |
| Goetz Kathleen | Director | – | Jun 8, 2026 | 1 |
| Tang Kevin C | Chief Executive Officer | 13,044,106Indirect | Jun 2, 2026 | 2 |
| Tang Capital Management LLC | 10% Owner | 13,044,106Indirect | Jun 2, 2026 | 1 |
| Hearne Michael S | Chief Financial Officer | 116,144 | May 20, 2026 | 1 |
| Cole Ryan | Chief Operating Officer | 116,144 | May 20, 2026 | 1 |
| Keenan Greg | SVP, Chief Medical Officer | 154,449 | Mar 10, 2026 | 3 |
| Greenleaf Peter | Chief Executive Officer | 1,840,379 | Mar 3, 2026 | 3 |
| Donley Matthew Maxwell | Chief Operating Officer | 680,299 | Mar 3, 2026 | 3 |
| Miller Joseph M | Chief Financial Officer | 576,421 | Mar 3, 2026 | 3 |
| Smith Karen L. | Director | 24,807 | Nov 25, 2024 | 0 |
| Leversage Jill | Director | 25,053 | Nov 25, 2024 | 0 |
| Jayne David R.W. | Director | 56,499 | Nov 25, 2024 | 0 |
| MacKay-Dunn R. Hector | Other: Former Director | 18,595 | Sep 20, 2024 | 0 |
| Habig Scott Michael | Chief Commercial Officer | 456,338 | Aug 8, 2024 | 0 |
| Billen Daniel | Director | 28,141 | May 22, 2024 | 0 |
| Balakrishnan Brinda | Director | 17,523 | May 22, 2024 | 0 |
| Knappertz Volker | EVP, Research and Development | 319,128 | Feb 29, 2024 | 0 |
| Foster Robert T | Director | – | Sep 22, 2023 | 0 |
| Milne George M Jr | Director | 78,733 | May 23, 2023 | 0 |
| Hagan Joseph P | Director | 11,961 | May 23, 2023 | 0 |
| Martin Michael Robert | Chief Business Officer | 259,162 | Mar 6, 2023 | 0 |
| Walbert Timothy P | Director | – | May 20, 2022 | 0 |
| Colao Massimilano | Chief Commercial Officer | 13,495 | Mar 4, 2022 | 0 |
| Huizinga Robert Bindert | EVP of Research | 69,379 | Mar 4, 2022 | 0 |
| Solomons Neil | Chief Medical Officer | 90,953 | Mar 4, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 29, 2021 (view filing) | Jul 28 | 1 day | Martin Michael RobertChief Business Officer | SSale | −5.00K | $13.86 | −$69.3K | −2.3%211.9K after | |
| Aug 10, 2021 (view filing) | Aug 9 | 1 day | Martin Michael RobertChief Business Officer | SSale | −5.00K | $16.01 | −$80.0K | −2.4%206.9K after | |
| Aug 10, 2021 (view filing) | Aug 9 | 1 day | Solomons NeilChief Medical Officer | SSale | −45.0K | $16.03 | −$721.4K | −24.0%142.3K after | |
| Aug 26, 2021 (view filing) | Aug 25 | 1 day | Solomons NeilChief Medical Officer | SSale | −5.00K | $15.85 | −$79.3K | −3.5%137.3K after | |
| Aug 27, 2021 (view filing) | Aug 26 | 1 day | Martin Michael RobertChief Business Officer | SSale | −22.5K | $17.81 | −$400.7K | −10.9%184.4K after | |
| Sep 8, 2021 (view filing) | Sep 7 | 1 day | Huizinga Robert BindertEVP of Research | SSale | −5.00K | $18.30 | −$91.5K | −3.5%138.6K after | |
| Sep 8, 2021 (view filing) | Sep 7 | 1 day | Martin Michael RobertChief Business Officer | SSale | −7.50K | $18.10 | −$135.8K | −4.1%176.9K after | |
| Sep 14, 2021 (view filing) | Sep 10 | 4 days | Solomons NeilChief Medical Officer | SSale | −150.0K | $19.84 | −$2.98M | −52.2%137.3K after | |
| Sep 14, 2021 (view filing) | Sep 10-14 | 4 days | Huizinga Robert BindertEVP of Research | SSale | −32.5K | $21.15 | −$687.3K | −23.5%106.1K after | 3 lots |
| Sep 14, 2021 (view filing) | Sep 10 | 4 days | Martin Michael RobertChief Business Officer | SSale | −25.0K | $19.80 | −$495.0K | −12.4%176.9K after | |
| Sep 14, 2021 (view filing) | Sep 14 | Same day | Martin Michael RobertChief Business Officer | SSale | −90.0K | $21.19 | −$1.91M | −33.7%176.9K after | |
| Sep 16, 2021 (view filing) | Sep 14 | 2 days | Martin Michael RobertChief Business Officer | SSale | −44.0K | $21.78 | −$958.2K | −19.9%176.9K after | 2 lots |
| Sep 22, 2021 (view filing) | Sep 20-21 | 2 days | Martin Michael RobertChief Business Officer | SSale | −116.0K | $23.44 | −$2.72M | −39.6%176.9K after | 3 lots |
| Sep 22, 2021 (view filing) | Sep 21 | 1 day | Huizinga Robert BindertEVP of Research | SSale | −32.5K | $23.99 | −$779.5K | −24.4%100.7K after | 2 lots |
| Oct 26, 2021 (view filing) | Oct 25 | 1 day | Huizinga Robert BindertEVP of Research | SSale | −130.0K | $29.75 | −$3.87M | −66.4%65.7K after | |
| Nov 3, 2021 (view filing) | Nov 1 | 2 days | Martin Michael RobertChief Business Officer | SSale | −45.0K | $31.64 | −$1.42M | −20.3%176.9K after | |
| Nov 3, 2021 (view filing) | Nov 1 | 2 days | Solomons NeilChief Medical Officer | SSale | −45.0K | $31.64 | −$1.42M | −24.7%137.3K after | |
| Nov 12, 2021 (view filing) | Nov 9 | 3 days | Solomons NeilChief Medical Officer | SSale | −50.0K | $30.17 | −$1.51M | −36.4%87.3K after | |
| Nov 12, 2021 (view filing) | Nov 10-11 | 2 days | Solomons NeilChief Medical Officer | SSale | −200.0K | $30.00 | −$6.00M | −69.6%87.3K after | 3 lots |
| Nov 12, 2021 (view filing) | Nov 9-11 | 3 days | Martin Michael RobertChief Business Officer | SSale | −121.0K | $30.59 | −$3.70M | −68.4%55.9K after | 4 lots |
| Nov 12, 2021 (view filing) | Nov 11 | 1 day | Martin Michael RobertChief Business Officer | SSale | −29.0K | $28.82 | −$835.8K | −30.3%66.9K after | |
| Dec 15, 2021 (view filing) | Dec 13 | 2 days | Leversage JillDirector | PPurchase | +1.60K | $20.04 | +$32.1K | +43.2%5.30K after | |
| Jan 4, 2022 (view filing) | Jan 3 | 1 day | Hagan Joseph PDirector | SSale | −40.0K | $22.59 | −$903.7K | −92.0%3.50K after | 2 lots |
| Mar 4, 2022 (view filing) | Mar 2 | 2 days | Huizinga Robert BindertEVP of Research | SSale | −4.85K | $12.01 | −$58.2K | −6.5%69.4K after | |
| Mar 4, 2022 (view filing) | Mar 2 | 2 days | Solomons NeilChief Medical Officer | SSale | −4.85K | $12.01 | −$58.2K | −5.1%91.0K after | |
| Mar 4, 2022 (view filing) | Mar 2 | 2 days | Greenleaf PeterChief Executive Officer | SSale | −9.07K | $12.01 | −$108.9K | −21.6%33.0K after | |
| Mar 4, 2022 (view filing) | Mar 2 | 2 days | Colao MassimilanoChief Commercial Officer | SSale | −3.21K | $12.01 | −$38.5K | −19.2%13.5K after | |
| Mar 4, 2022 (view filing) | Mar 2 | 2 days | Miller Joseph MChief Financial Officer | SSale | −3.06K | $12.01 | −$36.8K | −31.6%6.61K after | |
| Mar 4, 2022 (view filing) | Mar 2 | 2 days | Donley Matthew MaxwellEx VP, Intern'l Operations | SSale | −3.05K | $12.01 | −$36.7K | −15.8%16.2K after | |
| Mar 4, 2022 (view filing) | Mar 2 | 2 days | Martin Michael RobertChief Business Officer | SSale | −4.85K | $12.01 | −$58.2K | −7.5%59.5K after | |
| Mar 8, 2022 (view filing) | Mar 4 | 4 days | Milne George M JrDirector | PPurchase | +5.00K | $10.82 | +$54.1K | +11.1%50.0K after | |
| Mar 11, 2022 (view filing) | Mar 9 | 2 days | MacKay-Dunn R. HectorDirector | PPurchase | +5.00K | $11.00 | +$55.0K | +83.3%11.0K after | |
| Nov 9, 2022 (view filing) | Nov 7 | 2 days | Martin Michael RobertChief Business Officer | PPurchase | +30.0K | $5.16 | +$154.8K | +50.4%89.5K after | |
| Nov 14, 2022 (view filing) | Nov 9 | 5 days | Habig Scott MichaelChief Commercial Officer | PPurchase | +5.00K | $5.02 | +$25.1K | New position5.00K after | |
| Nov 23, 2022 (view filing) | Nov 21 | 2 days | Donley Matthew MaxwellEx VP, Internal Operations | PPurchase | +10.0K | $4.66 | +$46.6K | +55.8%27.9K after | |
| Mar 6, 2023 (view filing) | Mar 2 | 4 days | Milne George M JrDirector | PPurchase | +20.0K | $8.91 | +$178.2K | +40.0%70.0K after | |
| May 23, 2023 (view filing) | May 23 | Same day | Leversage JillDirector | SSale | −4.82K | $11.26 | −$54.2K | −20.6%18.5K after | |
| May 23, 2023 (view filing) | May 23 | Same day | MacKay-Dunn R. HectorDirector | SSale | −4.82K | $11.26 | −$54.3K | −16.6%24.2K after | |
| May 23, 2023 (view filing) | May 23 | Same day | Billen DanielDirector | SSale | −4.65K | $11.26 | −$52.4K | −12.2%33.4K after | |
| May 23, 2023 (view filing) | May 19 | 4 days | Hagan Joseph PDirector | SSale | −272 | $10.58 | −$2.88K | −2.2%12.0K after | |
| May 23, 2023 (view filing) | May 23 | Same day | Jayne David R.W.Director | SSale | −8.73K | $11.26 | −$98.3K | −15.0%49.3K after | |
| Feb 22, 2024 (view filing) | Mar 2, 2023 | 357 days | Greenleaf PeterChief Executive Officer | SSale | −33.0K | $8.78 | −$290.2K | −3.3%982.7K after | Amended |
| Feb 22, 2024 (view filing) | Mar 2, 2023 | 357 days | Miller Joseph MChief Financial Officer | SSale | −11.4K | $8.78 | −$100.1K | −3.3%331.1K after | Amended |
| Feb 22, 2024 (view filing) | Mar 2, 2023 | 357 days | Robertson Stephen P.EVP, General Counsel | SSale | −19.6K | $8.78 | −$172.5K | −6.1%303.1K after | Amended |
| Feb 22, 2024 (view filing) | Feb 20 | 2 days | Habig Scott MichaelChief Commercial Officer | SSale | −15.9K | $5.48 | −$87.0K | −3.1%492.4K after | |
| Feb 22, 2024 (view filing) | Feb 20 | 2 days | Knappertz VolkerEVP, Research and Development | SSale | −25.1K | $5.48 | −$137.8K | −7.2%324.1K after | |
| Feb 29, 2024 (view filing) | Feb 27 | 2 days | Knappertz VolkerEVP, Research and Development | SSale | −4.93K | $6.10 | −$30.1K | −1.5%319.1K after | |
| Mar 7, 2024 (view filing) | Mar 6 | 1 day | Robertson Stephen P.EVP, General Counsel | SSale | −57.7K | $5.60 | −$323.4K | −11.5%443.8K after | |
| Mar 7, 2024 (view filing) | Mar 6 | 1 day | Habig Scott MichaelChief Commercial Officer | SSale | −17.8K | $5.60 | −$99.6K | −3.6%474.6K after | |
| Mar 7, 2024 (view filing) | Mar 6 | 1 day | Donley Matthew MaxwellEVP, Ops & Strategy | SSale | −40.7K | $5.51 | −$224.1K | −6.5%584.1K after |